tiprankstipranks
Trending News
More News >
Vaccinex (VCNX)
:VCNX
US Market

Vaccinex (VCNX) Price & Analysis

Compare
305 Followers

VCNX Stock Chart & Stats


Financials

Options Prices

Currently, No data available
---

Ownership Overview

51.26%0.15%6.13%42.62%
51.26% Insiders
6.13% Other Institutional Investors
42.62% Public Companies and
Individual Investors

VCNX FAQ

What was Vaccinex’s price range in the past 12 months?
Vaccinex lowest stock price was $0.25 and its highest was $8.90 in the past 12 months.
    What is Vaccinex’s market cap?
    Vaccinex’s market cap is $2.35M.
      When is Vaccinex’s upcoming earnings report date?
      Vaccinex’s upcoming earnings report date is May 19, 2025 which is 25 days ago.
        How were Vaccinex’s earnings last quarter?
        Vaccinex released its earnings results on Mar 18, 2025. The company reported -$1.26 earnings per share for the quarter, missing the consensus estimate of N/A by -$1.26.
          Is Vaccinex overvalued?
          According to Wall Street analysts Vaccinex’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
            Does Vaccinex pay dividends?
            Vaccinex does not currently pay dividends.
            What is Vaccinex’s EPS estimate?
            Vaccinex’s EPS estimate for its next earnings report is not yet available.
            How many shares outstanding does Vaccinex have?
            Vaccinex has 2,676,637 shares outstanding.
              What happened to Vaccinex’s price movement after its last earnings report?
              Vaccinex reported an EPS of -$1.26 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -11.538%.
                Which hedge fund is a major shareholder of Vaccinex?
                Currently, no hedge funds are holding shares in VCNX

                Company Description

                Vaccinex

                Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs. The company offers its products for the treatment of cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate is pepinemab, a humanized monoclonal antibody that completed and planned Phase 1b/2 clinical trials for the treatment of non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), Huntington's disease, Alzheimer's disease, osteosarcoma, and melanoma. The company is also developing VX5, a human antibody to CXCL13 that is in preclinical development for the treatment of MS and for other autoimmune disorders. Vaccinex, Inc. was incorporated in 2001 and is headquartered in Rochester, New York.
                Similar Stocks
                Company
                Price & Change
                Follow
                Scinai Immunotherapeutics
                Qualigen Therapeutics
                Nucana
                CNS Pharmaceuticals
                Galecto
                Popular Stocks
                What am I Missing?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis